Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg sees upside risk to forecasts at Flutter

(Sharecast News) - Berenberg has reiterated a 'buy' rating for Flutter Entertainment, saying that the gambling and sports betting company's upcoming second-quarter results could "surprise to the upside". Operational results from the first quarter disappointed due to customer-friendly sporting results, though the acquisitions of Snaitech and NSX Group, which recently completed, are expected to add $1.1bn in revenue and $120m in EBITDA over 2025, according to Berenberg.

Meanwhile, taxation changes in New Jersey and Louisiana will be a headwind for the business, along with new rules of a fee per wager taken in Illinois. This will be partly offset by the acquisition of the remaining 5% of FanDuel that it didn't already own.

"State data also suggest operators have seen favourable win margins in June, which increases our confidence in the Q2 outlook," Berenberg said.

Despite the busy second quarter, the broker said it "remains bullish" given the quality of the business, its market-leading position across major markets and track record of inorganic growth.

"We think there is scope for Q2 to surprise to the upside based on operator-friendly sporting results in the US and remain of the view that FY25 guidance is well underpinned."

Shares were down 0.5% at 21,330p by 0925 BST, following a 6.5% climb over the past month.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.